Keyphrases
9p21 Locus
7%
Amino Acid Homeostasis
7%
Aneurysm Disease
7%
Angiotensin Receptor Blockers
8%
Angiotensin-converting Enzyme Inhibitor (ACEi)
9%
Aortic Valve Stenosis
7%
Aortopathy
7%
Arterial Inflammation
7%
Arterial Stiffness
7%
Atrial Fibrillation
17%
Beta-blockers
16%
Biology Study
9%
Biomarker Profile
7%
Cardiac Imaging Test
7%
Cardiac Rehabilitation
7%
Cardiovascular Effects
14%
Cardiovascular Magnetic Resonance
13%
Cardiovascular Outcomes
8%
Cardiovascular Risk
10%
Chromosome 9p21
7%
Chronic Heart Failure
17%
Clarithromycin
7%
Clinical Data
7%
Confidence Interval
24%
Coronary Artery Disease
29%
Coronary Heart Disease Events
7%
Cotransporter
7%
CV Events
7%
Dapagliflozin
7%
Desmosine
7%
Diabetic Cardiomyopathy
7%
Diabetic Patients
7%
Dilated Cardiomyopathy
7%
Disease Pathogenesis
7%
Disease Potential
7%
Disease Progression
8%
Disease-associated
8%
Echocardiographic
7%
Echocardiography
7%
Empagliflozin
11%
Epicardial Adipose Tissue
7%
Event Risk
8%
Exercise-based Cardiac Rehabilitation
7%
Extracellular Volume
6%
Failure Study
8%
Genome-wide Association
7%
Genomic Data
7%
Hazard Ratio
20%
Healthy Controls
7%
Heart Failure
54%
Heart Failure Patients
8%
Heart Failure Treatment
14%
Heart Failure with Preserved Ejection Fraction (HFpEF)
48%
Heart Rate
7%
Hypertensive Patients
7%
Individual Participant Data
7%
Inpatient Setting
7%
Insulin Resistance
6%
Iron Deficiency
7%
Iron Therapy
7%
Late Gadolinium Enhancement
7%
Left Ventricular Hypertrophy
8%
Left Ventricular Remodeling
7%
Loop Diuretics
16%
Major Adverse Cardiovascular Events
11%
Marfan Syndrome
7%
Mendelian Randomization
7%
Mendelian Randomization Analysis
7%
Meta-analysis
18%
Metabolic Modulation
7%
Metabolic Risk Factors
7%
Metabolic Traits
7%
Metformin
14%
Metformin Therapy
7%
Metformin Treatment
5%
Microvascular Disease
7%
Mitochondrial Dysfunction
7%
Neutrophil-to-lymphocyte Ratio
7%
New-onset Heart Failure
8%
Non-invasive Imaging
15%
Noninvasive Cardiac Imaging
7%
Novel Therapeutic Targets
9%
Odds Ratio
7%
P-glycoprotein (P-gp)
7%
Patient-controlled
7%
Patients with Cardiovascular Diseases
7%
Patients with Chronic Heart Failure
7%
Patients with Coronary Artery Disease
7%
Patients with Diabetes
7%
Patients with Heart Failure
31%
Placebo
15%
Plasma Proteomics
7%
Pooled Cohort Equations
7%
Population Cohort Study
7%
Population-based Cohort Study
7%
Preserved Ejection Fraction
7%
Prognostic Significance
9%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
7%
Proteomic Approach
7%
Randomized Controlled Trial
11%
Relative Risk
6%
Renal Effects
14%
Ruptured Abdominal Aortic Aneurysm (rAAA)
7%
Scotland
13%
Sinus Rhythm
14%
Sodium-glucose Cotransporter
7%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
Stable Coronary Artery Disease
7%
Subsequent Events
8%
Systematic Meta-analysis
14%
Tailored Treatment
9%
Tayside
5%
Type 2 Diabetes Mellitus (T2DM)
30%
Type 2 Diabetic Patients
16%
Up-titration
14%
Ventricular Arrhythmia
7%
Without Diabetes
7%
Worsening Heart Failure
7%
Medicine and Dentistry
Abdominal Aortic Aneurysm
7%
ACE Inhibitor
7%
Adipose Tissue
8%
Angiotensin Receptor Antagonist
7%
Aortopathy
7%
Arterial Stiffness
7%
Atrial Fibrillation
16%
Beta Adrenergic Receptor Blocking Agent
14%
Biological Marker
20%
Cardiac Imaging
7%
Cardiac Magnetic Resonance Imaging
14%
Cardiovascular Disease
19%
Cardiovascular Effect
14%
Cardiovascular Risk
10%
Cardiovascular System
12%
Cohort Analysis
8%
Congestive Heart Failure
82%
Coronary Artery Disease
18%
Cotransporter
7%
Desmosine
7%
Diabetes
7%
Diabetes Mellitus
7%
Diabetic Cardiomyopathy
7%
Dilated Cardiomyopathy
7%
Disease Exacerbation
7%
Diseases
8%
Ejection Fraction
8%
Empagliflozin
11%
Gadolinium
7%
Glycon
7%
Hazard Ratio
10%
Heart Failure with Preserved Ejection Fraction
22%
Heart Failure with Reduced Ejection Fraction
33%
Heart Rehabilitation
7%
Heart Ventricle Arrhythmia
7%
Insulin Resistance
6%
Iron Supplement
7%
Kexin
7%
Left Ventricular Hypertrophy
7%
Loop Diuretic Agent
14%
Lymphocyte
7%
Marfan Syndrome
7%
Maturity Onset Diabetes of the Young
26%
Mendelian Randomization Analysis
14%
Meta-Analysis
15%
Microangiopathy
7%
Neutrophil
7%
Odds Ratio
5%
Patient with Type 2 Diabetes
14%
Photograph
5%
Placebo
10%
Proteomics
7%
Randomized Controlled Trial
8%
Serine Proteinase
7%
Sinus Rhythm
14%
Sodium Glucose Cotransporter 2
7%
Subtilisin
7%
Systematic Review
15%
Urinary System
6%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Aortic Aneurysm
7%
Amino Acid
7%
Angiotensin Receptor Antagonist
8%
Atrial Fibrillation
16%
Beta Adrenergic Receptor Blocking Agent
16%
Biological Marker
11%
Cardiovascular Disease
12%
Cardiovascular Risk
16%
Clarithromycin
7%
Cohort Study
16%
Congestive Heart Failure
100%
Coronary Artery Disease
10%
Cotransporter
7%
Dapagliflozin
7%
Desmosine
7%
Diabetes Mellitus
7%
Diabetic Cardiomyopathy
7%
Dipeptidyl Carboxypeptidase Inhibitor
8%
Disease Exacerbation
7%
Diseases
8%
Empagliflozin
11%
Heart Failure with Preserved Ejection Fraction
14%
Heart Failure with Reduced Ejection Fraction
33%
Heart Infarction
5%
Heart Left Ventricle Hypertrophy
8%
Heart Ventricle Remodeling
7%
Iron
7%
Kexin
7%
Loop Diuretic Agent
16%
Metformin
14%
Microangiopathy
7%
Non Insulin Dependent Diabetes Mellitus
27%
P-Glycoprotein
7%
Placebo
18%
Randomized Controlled Trial
10%
Serine Proteinase
7%
Sodium Glucose Cotransporter 2
7%
Subtilisin
7%